CRF Health Announces Customer Expansion
CRF Health, a provider of electronic Clinical Outcome Assessment (eCOA) solutions, has been selected as a partner of choice by two top tier pharmaceutical companies.
CRF Health, a provider of electronic Clinical Outcome Assessment (eCOA) solutions, has been selected as a partner of choice by two top tier pharmaceutical companies. The agreements encompass two exclusive multi-year drug development initiatives covering 75 countries, 2,500 clinical research sites and more than 10,000 clinical trial participants. CRF Health’s TrialMax® platform will underpin both projects to drive data collection and supporting the collection of medication management data.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
